EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and genomic determinants associated with emergent ceftazidime–avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli

William C Shropshire iD, Jovan Borjan iD, Iris Y Fonseca, Kathlyn Pham, Melanie Guerrero, Karl Liboro, Allyson Young, Jovelle K Chung iD, Chin-Ting Wu iD, Ambrocio Manzanares, Micah M Bhatti iD, Nancy N Vuong und 5 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01860-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von William C Shropshire und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Aztreonam, Escherichia coli. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceftazidime–avibactam (CZA) has revolutionized care for carbapenem-resistant Enterobacterales infections, yet increasing New Delhi metallo-β-lactamase (NDM) prevalence has driven use of CZA plus aztreonam (ATM/CZA). We performed a comprehensive clinical and genomic analysis of ceftazidime–avibactam-resistant Escherichia coli (CZA-R- Ec ) collected at a tertiary cancer center (2017–2024) to identify patient- and isolate-level factors associated with reduced susceptibility to ATM/CZA and aztreonam–avibactam (AZA). CZA-R- Ec were isolated from 48 unique patients of whom 28 (58%) had confirmed infection. Oxford Nanopore Technologies long-read sequencing performed on 34 isolates from unique patients showed a diverse population enriched for ST167 (35%). Most sequenced isolates carried bla NDM-5 (26/34, 76%); among bla NDM-5 strains, 88% (23/26) harbored PBP3 YRI(K/N) insertions. Eleven isolates (32%) carried bla CMY variants, predominantly bla CMY-42 . Bla NDM-5 and bla CMY genes were largely plasmid-borne (IncF-type and IncI-γ/K1) in distinct genomic contexts. Among 32 confirmed CZA-R and ATM-R index isolates, 21 (66%) were ATM/CZA susceptible (MIC≤4 µg/mL; ATM/CZA-S). Compared to patients with ATM/CZA-S strains, patients with ATM/CZA non-susceptible (ATM/CZA-NS) isolates (ATM/CZA MIC>4 µg/mL) were significantly more likely to have had a prior E. coli infection (73% vs 0%, P -value = 1.6 × 10 −5 ). ATM/CZA-NS isolates were strongly associated with bla CMY carriage (81% vs 9% in ATM/CZA-S; adjusted P -value = 4 × 10 −4 ). Among 18 confirmed CZA-R- Ec bacteremias, 15 carried bla NDM ; 14/15 (92%) received ATM/CZA and all responded clinically. In conclusion, CZA-R- Ec at our center are dominated by PBP3-insertion, bla NDM-5 –positive lineages, for which ATM/CZA retains substantial in vitro activity and clinical efficacy. However, prior E. coli infection and bla CMY-42 variant positivity identify patients at risk for ATM/CZA non-susceptible infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsAztreonamEscherichia coliAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsDrug Combinationsbeta-LactamasesDrug Resistance, Multiple, BacterialEscherichia coli InfectionsPlasmidsThird Generation Cephalosporins

Stichwörter der Autor:innen

avibactam/aztreonamceftazidime/avibactamceftazidime/avibactam plus aztreonammetallo-beta-lactamasesnovel beta-lactam/beta-lactamase inhibitorsplasmid mediated AmpC genes

Substanzen

CeftazidimeAzabicyclo CompoundsAztreonamavibactam, ceftazidime drug combinationAnti-Bacterial AgentsDrug Combinationsbeta-LactamasesThird Generation Cephalosporins

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.
  • Department of Infection Control, Chief Quality Office, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Program in Diagnostic Genetics and Genomics, The University of Texas MD Anderson Cancer Center School of Health Professions, Houston, Texas, USA.

ORCID-Profile: William C Shropshire, Jovan Borjan, Jovelle K Chung, Chin-Ting Wu, Micah M Bhatti, Guy Handley, Amy Spallone, Roy F Chemaly, Samuel Shelburne

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Shropshire, W. C., Borjan, J., Fonseca, I. Y., Pham, K., Guerrero, M., Liboro, K., Young, A., Chung, J. K., Wu, C. T., Manzanares, A., Bhatti, M. M., Vuong, N. N., Handley, G., Spallone, A., Chemaly, R. F., Khan, A., & Shelburne, S. (2026). Clinical and genomic determinants associated with emergent ceftazidime–avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01860-25

Vancouver

Shropshire WC, Borjan J, Fonseca IY, Pham K, Guerrero M, Liboro K, et al. Clinical and genomic determinants associated with emergent ceftazidime–avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01860-25

BibTeX
@article{Shropshire2026,
  author = {Shropshire, William C and Borjan, Jovan and Fonseca, Iris Y and Pham, Kathlyn and Guerrero, Melanie and Liboro, Karl and Young, Allyson and Chung, Jovelle K and Wu, Chin-Ting and Manzanares, Ambrocio and Bhatti, Micah M and Vuong, Nancy N and Handley, Guy and Spallone, Amy and Chemaly, Roy F and Khan, Ayesha and Shelburne, Samuel},
  title = {Clinical and genomic determinants associated with emergent ceftazidime–avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01860-25}
}
Kostenlos starten →